These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 11193925)

  • 1. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I.
    Champoux JJ
    Ann N Y Acad Sci; 2000; 922():56-64. PubMed ID: 11193925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights into the function of type IB topoisomerases.
    Redinbo MR; Champoux JJ; Hol WG
    Curr Opin Struct Biol; 1999 Feb; 9(1):29-36. PubMed ID: 10047584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
    Streltsov SA
    J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA topoisomerase I changes the mode of interaction between camptothecin drugs and DNA as probed by UV-resonance Raman spectroscopy.
    Feofanov AV; Baranov AV; Fleury F; Riou JF; Nabiev IR; Manfait M
    FEBS Lett; 1996 Nov; 396(2-3):289-92. PubMed ID: 8915005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The human DNA topoisomerase I mutant Gly717Asp: Higher religation rate is not always associated with camptothecin resistance.
    Wang Z; D'Annessa I; Tesauro C; Ottaviani A; Soren BC; Dasari JB; Messina B; Thareparambil A; Fiorani P
    Arch Biochem Biophys; 2019 Mar; 663():165-172. PubMed ID: 30653963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in topoisomerase I-targeting agents, camptothecin analogues.
    Kim DK; Lee N
    Mini Rev Med Chem; 2002 Dec; 2(6):611-9. PubMed ID: 12370044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Camptothecins as probes of the microenvironments of topoisomerase I--DNA complexes.
    Hecht SM
    Ann N Y Acad Sci; 2000; 922():76-91. PubMed ID: 11193927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.
    Kerrigan JE; Pilch DS
    Biochemistry; 2001 Aug; 40(33):9792-8. PubMed ID: 11502172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin.
    Hautefaye P; Cimetière B; Pierré A; Léonce S; Hickman J; Laine W; Bailly C; Lavielle G
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2731-5. PubMed ID: 12873503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
    Takagi K; Dexheimer TS; Redon C; Sordet O; Agama K; Lavielle G; Pierré A; Bates SE; Pommier Y
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3229-38. PubMed ID: 18089716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
    Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
    J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
    Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
    Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats.
    Barth SW; Briviba K; Watzl B; Jäger N; Marko D; Esselen M
    Biotechnol J; 2010 Mar; 5(3):321-7. PubMed ID: 20213647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and properties of camptothecin derivatives, their protonated forms, and model interaction with the topoisomerase I-DNA complex.
    Ivanova B; Spiteller M
    Biopolymers; 2012 Feb; 97(2):134-44. PubMed ID: 21898362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks.
    Murren JR; Beidler DR; Cheng YC
    Ann N Y Acad Sci; 1996 Dec; 803():74-92. PubMed ID: 8993502
    [No Abstract]   [Full Text] [Related]  

  • 16. 14-azacamptothecin: a potent water-soluble topoisomerase I poison.
    Cheng K; Rahier NJ; Eisenhauer BM; Gao R; Thomas SJ; Hecht SM
    J Am Chem Soc; 2005 Jan; 127(3):838-9. PubMed ID: 15656613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the topoisomerase I cleavage complexes formed by camptothecin and wakayin, a DNA-intercalating marine natural product.
    Kokoshka JM; Capson TL; Holden JA; Ireland CM; Barrows LR
    Anticancer Drugs; 1996 Sep; 7(7):758-65. PubMed ID: 8949987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luotonin A. A naturally occurring human DNA topoisomerase I poison.
    Cagir A; Jones SH; Gao R; Eisenhauer BM; Hecht SM
    J Am Chem Soc; 2003 Nov; 125(45):13628-9. PubMed ID: 14599178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topological nuts and bolts.
    Nash HA
    Science; 1998 Mar; 279(5356):1490-1. PubMed ID: 9508726
    [No Abstract]   [Full Text] [Related]  

  • 20. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives.
    Chowdhury AR; Mandal S; Mittra B; Sharma S; Mukhopadhyay S; Majumder HK
    Med Sci Monit; 2002 Jul; 8(7):BR254-65. PubMed ID: 12118187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.